Abstract 2131: Hyperpolarized carbon-13 MRI for early treatment response assessment in pancreatic ductal adenocarcinoma patients.

作者：Minjie Zhu, Hsin-yu Chen, Tanner Nickles, Robert Bok, Andrew H. Ko, Zhen Wang, Jeremy W. Gordon · 发表于：Cancer Research · 年份：2026 · DOI：10.1158/1538-7445.am2026-2131 · 研究领域：Advanced NMR Techniques and Applications、Radiomics and Machine Learning in Medical Imaging、Cancer, Hypoxia, and Metabolism

Abstract Current methods for monitoring treatment response in pancreatic ductal adenocarcinoma (PDA), primarily relying tumor size measurement using response evaluation criteria in solid tumors (RECIST), are often delayed and limited by the infiltrative nature of the disease. Timely, non-invasive assessment is crucial for adapting therapies for non-responders. PDA tumor cells are characterized by significant metabolic reprogramming, driven by KRAS oncogene mutations, which enhance glycolysis and lactate production while downregulating alanine aminotransferase, which mediates pyruvate to alanine conversion. Hyperpolarized (HP) carbon-13 (13C) magnetic resonance imaging (MRI) offers a non-invasive solution to interrogate these metabolic changes. Utilizing dynamic nuclear polarization, this technique provides unprecedented sensitivity(> 10,000-fold signal increase) and chemical specificity for rapid and pathway-specific investigation of dynamic metabolic processes that were previously inaccessible by 1H MRI or CT. Pre-clinical studies have shown HP 13C MRI using [1-13C]pyruvate as substrate can detect and monitor PDA precursor lesion progression, with an increase in the lactate-to-pyruvate ratio and decrease in the alanine-to-pyruvate ratio observed in the affected mice pancreas. Initial clinical studies have further demonstrated the feasibility and safety of HP 13C MRI for quantifying metabolism in PDA patients. In this ongoing study, five PDA patients underwent multipar...